(2S,3S,4S,5R,6R)-6-[(1S)-1-(4-fluorophenyl)-3-[(2S,3R)-1-(4-fluorophenyl)-2-(4-hydroxyphenyl)-4-oxoazetidin-3-yl]propoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid

• ChemBase编号: 168849
• 分子式: C30H29F2NO9
• 平均质量: 585.5493664
• 单一同位素质量: 585.18103795
• SMILES: C1(=O)[C@@H]([C@H](N1c1ccc(cc1)F)c1ccc(cc1)O)CC[C@@H](c1ccc(cc1)F)O[C@@H]1O[C@H]([C@H]([C@@H]([C@@H]1O)O)O)C(=O)O
• Canonical SMILES: Oc1ccc(cc1)[C@@H]1[C@@H](CC[C@@H](c2ccc(cc2)F)O[C@@H]2O[C@@H](C(=O)O)[C@H]([C@@H]([C@@H]2O)O)O)C(=O)N1c1ccc(cc1)F
• InChI: InChI=1S/C30H29F2NO9/c31-17-5-1-15(2-6-17)22(41-30-26(37)24(35)25(36)27(42-30)29(39)40)14-13-21-23(16-3-11-20(34)12-4-16)33(28(21)38)19-9-7-18(32)8-10-19/h1-12,21-27,30,34-37H,13-14H2,(H,39,40)/t21-,22+,23-,24+,25+,26-,27+,30-/m1/s1
• InChIKey: MPXLJVWGRVISEQ-ADEYADIWSA-N

名称和登记号

名称

• IUPAC标准名: (2S,3S,4S,5R,6R)-6-[(1S)-1-(4-fluorophenyl)-3-[(2S,3R)-1-(4-fluorophenyl)-2-(4-hydroxyphenyl)-4-oxoazetidin-3-yl]propoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid
• IUPAC传统名: (2S,3S,4S,5R,6R)-6-[(1S)-1-(4-fluorophenyl)-3-[(2S,3R)-1-(4-fluorophenyl)-2-(4-hydroxyphenyl)-4-oxoazetidin-3-yl]propoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid
• 别名: (1S)-1-(4-Fluorophenyl)-3-[(2S,3R)-1-(4-fluorophenyl)-2-(4-hydroxyphenyl)-4-oxo-3-azetidinyl]propyl β-D-Glucopyranosiduronic Acid; SCH 488128; Ezetimibe Hydroxy β-D-Glucuronide

登记号

• CAS号: 536709-33-8
• PubChem SID: 162262981
• PubChem CID: 49849668

理论计算性质

• Acid pKa: 3.3605328
• 质子受体: 9
• 质子供体: 5
• LogD (pH = 5.5): 0.9832578
• LogD (pH = 7.4): -0.3075385
• Log P: 3.1085668
• 摩尔折射率: 141.1424 cm^3
• 极化性: 55.269604 Å^3
• 极化表面积: 156.99 Å^2
• 可自由旋转的化学键: 9
• 里宾斯基五规则: false

分子性质

理化性质

• 溶解度: DMSO; Methanol
• 外观: Off-White Solid
• 熔点: 196-198°C

安全信息

• 保存条件: -20°C Freezer

详细说明

Toronto Research Chemicals - E975035

A metabolite of Ezetimibe. Antilipemic.

参考文献

• Shah, V., et al.: J. Pharm. Sci., 17, 1551 (2000)
• Van Heek, M., et al.: Br. J. Pharmacol., 134, 409 (2000)
• Patrick, J., et al.: Drug Metab. Dispos., 30, 430 (2000)